Table 2.
Baseline characteristics
| Group I with CIED (%) | Group II without CIED (%) | p value | |
|---|---|---|---|
| Total number of patients | 31 | 243 | |
| Gender male | 20 (64.5) | 152 (62.6) | 0.831 |
| Age in years | 73.7 ± 5.4 | 69.3 ± 8.2 | < 0.001 |
| AF-type | |||
| Paroxysmal AF | 16 (51.6) | 118 (48.6) | 0.736 |
| Persistent | 5 (16.1) | 54 (22.2) | |
| Permanent | 10 (32.3) | 71 (29.2) | |
| CHA2DS2-VASc (mean ± SD) | 4.3 ± 1.5 | 3.8 ± 1.5 | 0.104 |
| Low–intermediate risk (0–3) | 9 (29.0) | 111 (45.7) | 0.079 |
| High risk (> 3) | 22 (71.0) | 132 (54.3) | |
| HAS-BLED | 3.3 ± 1.0 | 2.8 ± 1.0 | 0.021 |
| Low–intermediate risk (0–3) | 17 (54.8) | 188 (77.4) | 0.007 |
| High risk (> 3) | 14 (45.2) | 55 (22.6) | |
| History of ischemic stroke | 7 (22.6) | 80 (32.9) | 0.244 |
| History of major bleeding: | 26 (83.9) | 134 (55.1) | 0.002 |
| Intracranial haemorrhage | 15 (48.4) | 75 (30.9) | 0.050 |
| Other | 13 (41.9) | 66 (27.2) | 0.087 |
| APT or (N)OAC use prior to LAAO *: | |||
| None | 5 (16.1) | 42 (17.3) | 0.872 |
| Aspirin | 13 (44.8) | 46 (20.5) | 0.004 |
| Clopidogrel | 3 (9.7) | 28 (11.5) | 1.000 |
| VKA | 7 (22.6) | 98 (40.3) | 0.056 |
| NOAC | 4 (12.9) | 41 (16.9) | 0.574 |
| Persantin | 2 (6.6) | 4 (1.6) | 0.139 |
AF, atrial fibrillation; CIED, cardiac implantable electronic device; (N)OAC, (novel) oral anticoagulation; SD, standard deviation; VKA, vitamin K antagonist
*Medication use scored at day directly before LAAO